Showing results (1591-1600 of 1,672) with videos related to
Sort By:
Pageof 168
Plos One|March 22, 2014
High genetic diversity and adaptive potential of two simian hemorrhagic fever viruses in a wild primate populationAdam L Bailey, Michael Lauck, Andrea Weiler, et al.Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.Proceedings of the National Academy of Sciences of the United States of America|November 16, 2021
Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosisXinbo Zhang, Jeffrey G McDonald, Binod Aryal, et al.Medrxiv : the Preprint Server for Health Sciences|August 30, 2023
Timing dependent synergies between motor cortex and posterior spinal stimulation in humansJames R McIntosh, Evan F Joiner, Jacob L Goldberg, et al.Journal of Medicinal Chemistry|August 1, 1997
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbitsL J MacPherson, E K Bayburt, M P Capparelli, et al.Bioconjugate Chemistry|April 22, 2016
Biotechnology Based Process for Production of a Disulfide-Bridged PeptideAnimesh Goswami, Steven L Goldberg, Ronald L Hanson, et al.Journal of Virology|December 16, 2016
Within-Host Evolution of Simian Arteriviruses in Crab-Eating MacaquesLouise H Moncla, Andrea M Weiler, Gabrielle Barry, et al.Cell|August 21, 2012
Cancer vulnerabilities unveiled by genomic lossDeepak Nijhawan, Travis I Zack, Yin Ren, et al.Genome Biology|September 27, 2025
Hybrid BAG-seq: DNA and RNA from the same single nucleus reveals interactions between genomic and transcriptomic landscapes in human tumor samplesSiran Li, Joan Alexander, Jude Kendall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.Pageof 168